This love month, let us not only think of romance but how to take care of our heart. Heart failure is a condition that develops when the heart fails to pump the needed blood to keep the body strong and healthy. It follows a continuum of cardiovascular events which may…
(Photo by Paul ELLIS / AFP / MANILA BULLETIN)
With the FDA’s approval, Dapagliflozin is the first and only drug under the sodium glucose transport protein 2 inhibitor (SGLT2i) class approved to treat heart failure in adult patients with reduced ejection fraction (pumapalyang puso), AstraZeneca Philippines said in statement.
The multinational pharmaceutical company noted that the Dapagliflozin, a medicine for diabetes, is the only SGLT2i proven to significantly prevent cardiovascular death and death due to other causes among patients with heart failure.
AstraZeneca Philippines Country President Lotis Ramin expressed AstraZeneca’s commitment to uplift the standard of care of Filipino patients by providing them with innovative and accessible treatment.